文献速递心外重症与机械循环支持

早期干预乳酸脱氢酶升高改善HeartMate II左心室辅助装置患者临床结局:PREVENT研究启示

Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study.
PubMed 文献 · J Heart Lung Transplant · 2017-10-24

基于前瞻性多中心PREVENT研究268例植入后≥30天有≥2次LDH测量的患者,评估LDH升高与临床结局、早期药物干预效果及危险因素。中度LDH升高(2.5-3.2×ULN)时早期药物干预较更高水平(>3.2×ULN)更易持续缓解且6个月无泵血栓或手术干预(91% vs 26%,p=0.002)。

要点

  • LDH升高患者6个月无卒中生存率显著低于LDH正常者
  • 中度LDH升高(2.5-3.2×ULN)早期药物干预可成功缓解症状
  • 早期干预组6个月无泵血栓或手术干预比例达91%

核心结论

  • 早期药物干预可成功缓解中度LDH升高(2.5-3.2×ULN),治疗后6个月死亡或泵血栓发生率低。

研究设计与样本

  • 前瞻性、多中心PREVENT研究,纳入268例植入后≥30天有≥2次LDH测量的患者。

主要发现

  • LDH升高者6个月无卒中生存率低于LDH正常者(83±6% vs 93±2%,p=0.035)。
  • LDH升高者中19%未干预自行缓解,43%经强化药物治疗缓解,38%需手术干预。
  • 仅药物治疗者治疗后6个月生存率94±6%,16例中15例症状持续缓解,1例于初始治疗后171天(植入后202天)发生泵血栓。
  • 中度LDH升高(2.5-3.2×ULN)早期药物干预较更高水平(>3.2×ULN)6个月无泵血栓或手术干预比例更高(91% vs 26%,p=0.002)。

关键数值与推荐

  • LDH升高定义为连续2次测量LDH≥2.5×正常上限(ULN)。
  • 中度升高定义为2.5-3.2×ULN,更高水平为>3.2×ULN。

临床怎么用

  • 对HeartMate II患者LDH中度升高(2.5-3.2×ULN)应尽早强化药物治疗以缓解症状并降低泵血栓风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemolysis, assessed by elevated serum lactate dehydrogenase (LDH), is strongly associated with HeartMate II pump thrombosis (PT). However, it is unknown whether early intervention for elevated LDH circumvents the risk of serious PT requiring pump exchange. We sought to evaluate the relationship between elevated LDH and clinical outcomes, the effectiveness of early medical intervention, and risk factors for elevated LDH. METHODS: We studied 268 patients in the prospective, multicenter PREVENT study who had 2 or more LDH measurements at ≥30 days post-implant. Elevated LDH was defined as LDH ≥2.5× upper limit of normal (ULN) for 2 consecutive measurements. RESULTS: Fourteen percent of patients had elevated LDH. Stroke-free survival at 6 months was lower in patients with elevated LDH vs patients with normal LDH (83 ± 6% vs 93 ± 2%, p = 0.035). Elevated LDH resolved without intervention in 19% of patients, with intensified medical therapy in 43% and required surgical intervention in 38%. For patients receiving only medical therapy, survival was 94 ± 6% at 6 months post-treatment. In this subgroup, resolution of symptoms with intensified medical therapy was sustained in 15 of 16 patients, with PT occurring in 1 patient at 171 days after initial treatment for elevated LDH (202 days post-implant). Early medical intervention at moderately elevated LDH (2.5× to 3.2× ULN), as compared with higher levels (>3.2× ULN), led to more sustained resolution of symptoms without subsequent PT or need for surgical intervention (91% vs 26% at 6 months post-treatment, p = 0.002). CONCLUSIONS: Early medical intervention can successfully resolve moderate LDH elevations (2.5× to 3.2× ULN) with a low incidence of death or PT at 6 months post-treatment.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Thenappan T, Stulak JM, Agarwal R, et al. Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study. J Heart Lung Transplant. 2017. PMID: 29153636. doi:10.1016/j.healun.2017.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。